CA
NZ
UK
AU
IND
US
Relay Therapeutics, Inc. (NASDAQ:RLAY), a Cambridge, Massachusetts-based clinical-stage precision medicine company, saw its shares decline more than 5% in Wednesday's session on above-average trading volume. The move stood out because the broader biotech sector traded constructively during the same period, with the Russell 1000 …
Biohaven Ltd. (NYSE:BHVN), a clinical-stage biopharmaceutical company based in New Haven, Connecticut, saw its shares surge after announcing a strategic global licensing agreement with SK Biopharmaceuticals. The deal grants SK Biopharmaceuticals an exclusive worldwide license to Biohaven's Kv7 ion channel platform, led by opakalim, …
Generate Biomedicines, Inc. (NASDAQ:GENB), a Somerville, Massachusetts-based clinical-stage company that appliesMachine Learningto design protein-based therapeutics, saw its shares plunge more than 20% in Wednesday's trading. The stock gave back a substantial portion of the gains it had built since its February 2026 initial public …
argenx SE (NASDAQ:ARGX), a global immunology company headquartered in Amsterdam, saw its shares climb toward 52 week highs following a wave of bullish analyst commentary. The advance follows the company's positive Phase 3 ALKIVIA topline results in autoimmune myositis, announced August 17.
BioArctic AB (OTC: BRCTF) (publ) is a leading biotechnology company with a market capitalization of approximately $29.3 billion. This change underscores BioArctic’s strong execution and potential within the healthcare sector. Investors are likely to find reassurance in the solid earnings performance, which contributes positively …
This approval applies to two new treatment regimens, specifically Ziihera combined with Tevimbra (tislelizumab-jsgr) and fluoropyrimidine-plus-platinum chemotherapy, which are recommended for HER2-positive patients with either IHC 3+ or IHC 2+/ISH+ status. This significant milestone introduces a new therapeutic option for a patient population in …
Vyome Holdings, Inc. (NASDAQ: HIND) recorded approximately $7.9 million in cash and cash equivalents as of June 30, 2026, marking a significant rise from approximately $5.0 million at the end of 2025. This improvement inLiquiditysupports the company’s operational strategy as it focuses on advancing …
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) has established September 4, 2026, as the record date for the distribution of contingent value rights (CVRs). This announcement comes as a significant step in connection with the company's intended merger with Korsana Biosciences, marking progress in the overall …
PDS Biotechnology Corp (NASDAQ: PDSB) is executing a significant workforce reduction that will affect about 36% of its employees, a strategic move made official on August 6, 2026. This reduction aligns the company’s operational costs with its shifting priorities, particularly focusing on the advancement …
Adaptin Bio, Inc. (OTC: APTN) has commenced enrollment for a Phase 1 clinical trial assessing its investigational therapy, APTN-101, for glioblastoma, an aggressive form of brain cancer. This study represents a critical step toward evaluating APTN-101’s safety and efficacy in treating this severe illness, …
Please wait processing your request...